BioCentury
ARTICLE | Clinical News

Allos completes Phase II enrollment

August 2, 2000 7:00 AM UTC

ALTH enrolled 50 patients with non-small lung cancer undergoing chemotherapy followed by radiation treatment combined with RSR13, the company's small molecule allosteric hemoglobin modifier radioenhan...